| Document |
Document Title |
|
WO/2024/097629A1 |
The present disclosure relates to compounds of Formula (I): or pharmaceutically acceptable salts or isotopically labeled derivatives thereof, wherein A is a 6- to 10- membered bridged bicyclic heterocycloalkyl comprising at least one oxy...
|
|
WO/2024/096707A1 |
The present invention relates to: a composition for preventing or treating Moyamoya disease, comprising, as an active ingredient, miRNAs or extracellular vesicles comprising same; and a composition for preventing or treating Moyamoya dis...
|
|
WO/2024/097284A1 |
Provided herein are methods, uses, and compositions for treating atrial fibrillation in a patient, such as a patient exhibiting hypertrophic cardiomyopathy.
|
|
WO/2024/098009A1 |
Compositions and methods for treating or preventing a condition related to myocardial infarction and infarct expansion, extension, and/or dilation following a cardiovascular disorder incident (e.g., post-myocardial infarction) using an e...
|
|
WO/2024/094211A1 |
The present invention relates to mucosal drug delivery systems, and specifically to a lipid composition; the lipid composition containing a therapeutic agent and/or prophylactic agent such as RNA can be used for mucosal delivery of the t...
|
|
WO/2024/097251A1 |
In one aspect, the present disclosure describes methods which may be used to create ICWs and thereby regulate calcium signaling. These methods may employ a light-stimulated MM to generate an ICW and that ICW may be used to induce muscle ...
|
|
WO/2024/095005A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: wherein V, W, X, Y, Z, A1, A2, A3, A4, A5, A6, A7, A8, A9 and R3 are as defined in the specification,...
|
|
WO/2024/098071A1 |
This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of cardiovascular disease/disorder and/or reducing risk factors thereof by inducing re...
|
|
WO/2024/096424A1 |
The present invention relates to a pharmaceutical composition for preventing or treating ischemic diseases, the pharmaceutical composition containing liposome nanoparticles in which an angiogenic QK peptide is loaded on the surface of a ...
|
|
WO/2024/096066A1 |
The present disclosure provides a cyclic peptide derivative composition for treating or preventing central nervous system injury/disease.　The present disclosure pertains to a composition comprising: a compound for treating or preventin...
|
|
WO/2024/095151A1 |
In accordance with the inventive concepts, provided is a cryo-delivery apparatus and method. In various embodiments, the cryo-delivery apparatus is useful to perform a percutaneous cryo-delivery method. In one embodiment, a therapeutic i...
|
|
WO/2024/093412A1 |
A heterocyclic compound, a preparation method therefor, and an application thereof. The structural formula of the heterocyclic compound is as represented by formula I. The present compound has excellent bioavailability, can improve cereb...
|
|
WO/2024/094606A1 |
A composition containing a combination of at least one fiber and at least one probiotic can be orally administered to a subject in an amount effective to regulate gut bacteria association with cholesterol levels in the blood of the subje...
|
|
WO/2024/097387A1 |
The present invention provides compounds, compositions, and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.
|
|
WO/2024/093944A1 |
The present invention relates to the field of pharmaceutical chemicals, and in particular, to a solid dispersion of a curcumin derivative C66, a method for preparing same, and use thereof. In the solid dispersion described by the present...
|
|
WO/2024/097125A1 |
The present disclosure provides for treating pulmonary hypertension by administering to a subject suffering from pulmonary hypertension a therapeutically effective amount of a non-oral therapeutic agent for treating pulmonary hypertensio...
|
|
WO/2023/245175A3 |
This disclosure relates to lipid nanoparticle composition comprising polyamidoamine (PAMAM) dendrimer (G0-C14), cholesterol, polyethylene glycol 2000 (PEG), 1,2-Distearoyl-sn-glycero-3- phosphoethanolamine-Poly(ethylene glycol) (DSPE-PEG...
|
|
WO/2024/095003A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: Formula (I) wherein Z, X, R1, R2, R4, R5, R6 and R7 are as defined in the specification, processes fo...
|
|
WO/2024/092040A1 |
Provided herein are compounds that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for ...
|
|
WO/2024/092037A1 |
Provided herein are compounds that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for ...
|
|
WO/2024/092226A1 |
The present invention provides an oligomer capable of binding to a target site of precursor messenger RNA (pre-mRNA) of myosin phosphatase target subunit (Mypt1) in cells, wherein binding of the oligomer to the target site of the pre-mRN...
|
|
WO/2024/091489A1 |
Provided are compounds of the Formula (I):; or pharmaceutically acceptable salts thereof, which can be useful for the inhibition of Drp 1 and in the treatment of a variety of Drp 1l mediated conditions or diseases.
|
|
WO/2024/087673A1 |
An antiplatelet drug, comprising a platelet inhibitory molecule, a linker, and a capture group. The capture group is a functional group of click chemistry reaction. The antiplatelet drug has good antiplatelet activity, and can be used in...
|
|
WO/2024/092043A1 |
Provided herein are compounds that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for ...
|
|
WO/2024/092095A1 |
Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of a vascular disease, such as coronary artery disease (CAD), in a subject. In particular, provided are methods and compositions for treating a vasc...
|
|
WO/2024/089196A1 |
The present disclosure relates to dosage regimens for the administration of a recombinant apyrase protein and their medical use in the treatment of ischemic events in a patient, such as ST-segment elevation myocardial infarction and acut...
|
|
WO/2024/090329A1 |
The present inventors have found that a pyridoxal synthetic enzyme Pyridoxamine-5'-phosphate oxidase (PNPO) acts as an oxygen sensing mechanism for a novel pathway that is independent from an HIF pathway in chronic hypoxia. A pharmaceuti...
|
|
WO/2023/039449A9 |
The present disclosure provides methods and kits for identifying and treating individuals at risk of or suffering from amyloid transthyretin cardiomyopathy. In general, detection or measurement of one or more biomarkers, such as TnI, PKM...
|
|
WO/2024/091451A1 |
Disclosed herein are compositions and methods useful for the treatment or amelioration of various diseases, disorders, or conditions. Some aspects pertain to a pharmaceutical composition comprising 17-ethynyl-10R, 13S-dimethyl 2, 3, 4, 7...
|
|
WO/2024/091148A2 |
The invention relates to the chemical and pharmaceutical industry, and more particularly to a liquid balneological concentrate for preparing health-giving and therapeutic full or partial baths at health resorts and in other medical and w...
|
|
WO/2024/088110A1 |
Provided are a heterocyclic macrocyclic compound containing an indazole structure and used as a protein kinase inhibitor, and a preparation method therefor. The compound has the structure represented by general formula (I). Additionally ...
|
|
WO/2024/089226A1 |
The present disclosure relates to phenethylamine compounds, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, polymorphs, or prodrugs thereof, to pharmaceutical compositions, and in some embodiments, to serotonin...
|
|
WO/2024/088156A1 |
The present invention relates to a novel use of recombinant human ocriplasmin in the preparation of a drug for treating and/or preventing a choroidal vascular disease.
|
|
WO/2024/092015A1 |
An in vitro method of preparing a population of hypoimmune mammalian stem cells includes providing a population of isolated mammalian stem cells, wherein the isolated mammalian stem cells express a cell adhesion molecule; and modifying t...
|
|
WO/2024/088190A1 |
Provided is an RNA inhibitor for inhibiting LPA gene expression or a pharmaceutically acceptable salt thereof. The RNA inhibitor is formed by base pairing of a sense strand and an antisense strand having a chain length of 15-30, and the ...
|
|
WO/2024/092210A1 |
Provided herein are methods to treat fibrosis and/or inhibit angiogenesis.
|
|
WO/2024/082009A1 |
This disclosure relates generally to methods and agents for treating cardiomyopathies. More particularly, the present disclosure relates to the use of CD14 antagonist antigen-binding molecules for treating a cardiomyopathy, including all...
|
|
WO/2024/084428A1 |
The present invention relates to a composition of substances effective in the prevention and/or treatment of cardiovascular system diseases, respiratory system diseases, immune system diseases, reproductive system diseases, nervous syste...
|
|
WO/2024/085700A1 |
The present invention relates to a composition for ameliorating, preventing, or treating myocardial damage caused by cardiotoxic drugs. The composition contains at least one selected from the group consisting of a Cirsium setidens extrac...
|
|
WO/2024/082008A1 |
This disclosure relates generally to methods and agents for treating arrhythmogenic cardiomyopathy (ACM). More particularly, the present disclosure relates to the use of CD14 antagonist antigen-binding molecules for treating ACM, includi...
|
|
WO/2024/086342A1 |
The present disclosure provides methods for generating and/or purifying secretomes, extracellular vesicles, and fractions thereof, from progenitor cells; and provides compositions containing such generated secretomes, extracellular vesic...
|
|
WO/2024/085558A1 |
The present invention relates to a composition for preventing or treating OSCAR-induced diseases, containing brivudine as an active ingredient, and a method for treating OSCAR-induced diseases, comprising the step of administering the co...
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/084390A1 |
Described herein are compounds of Formula I, wherein the variables are defined herein, their use as activators from AMPK, pharmaceutical compositions containing such compounds and their use to treat, for example, heart failure or periphe...
|
|
WO/2024/084421A1 |
The present invention provides methods of treatment, diagnostics, kits, and formulations for treating a subject having one or more genetic variations in an Actin alpha 2 (ACTA2) gene involving administering a therapeutically effective am...
|
|
WO/2024/083176A1 |
Disclosed are the uses of amniotic fluid in the preparation of a drug for treating and/or preventing macrophage-mediated diseases, a drug for treating and/or preventing type M1 macrophage-mediated diseases, a drug for treating and/or pre...
|
|
WO/2024/083919A1 |
The present invention relates to use of inhibitors of the potassium channel Kv1.3 in therapeutic methods, in particular wherein the methods comprise administering the inhibitor to a subject at particular intervals.
|
|
WO/2024/085725A1 |
The present invention pertains to a novel compound derivative and a pharmacological use thereof and specifically to a novel 1,1-dioxo-1,2-benzisothiazole derivative or novel 3-citryl-1H-pyrazole derivatives possessing antiplatelet activi...
|
|
WO/2024/083861A1 |
The present invention relates to 1-(sulfonyl)-N-phenylpyrrolidine-2-carboxamides derivatives according to formula (I) for use in the prevention and/or treatment of a disease or disorder selected from an autoimmune disease, organ transpla...
|
|
WO/2024/083937A2 |
The present invention relates to a method for imaging an anatomical structure in a subject in need thereof, comprising the following steps: a) providing an injectable pharmaceutical composition comprising, as a contrast agent, at least o...
|
